MONTREAL, QUEBEC -- (MARKET WIRE) -- January 31, 2007 -- Theratechnologies (TSX: TH) announced today that it has enrolled the first patient in its second Phase 3 clinical trial testing TH9507 in HIV-associated lipodystrophy. The objective of the new study is to confirm, for regulatory purposes, the beneficial effects seen in the Company’s first Phase 3 study, the top-line results of which were made public in December 2006.
